Decrease (-) Restore Default Increase (+)
In This Section Texas Health Research & Education Institute

Clinical Trials

Disease or Condition   Lung Cancer
Title   Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Description   Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer. This randomized phase III trial is studying chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery.
IRB Number   Pro241
Inclusion/Notes   INCLUSION:
  • Patients diagnosed with NSCLC [Stage IB(= 4cm)-IIIA , T2-3N0, T1-3N1, T1-3N2] who have had resection, either pre-operative or intraopertive mediastinal lymph node sampling.

  • Must be 6-12 weeks post-thoracotomy at randomization.

  • Patients who have been treated with systemic chemotherapy.

  • Patients with hormonal cancer therapy or radiation therapy (except palliative) within 5 years of enrollment.

  • Patients with a history of cancer within the last 5 years except for carcinoma in situ of the cervix or completely resected non-melanoma skin cancer.

  • Patients with a history of myocardial infarction or evidence of arterial thrombotic disease within 12 months of randomization.

  • Patients with a history of CVA or TIA, bleeding diathesis or coagulopathy.

  • Patients with an abdominal fistula, gastronintestinal perforation, intra-abdominal abcess, serious non-healing wound, ulcer, bone fracture or have undergone surgery, open biopsy or significant traumatic injury within 28 days prior to randomization or core biopsy within 7 days of randomization.
Status   Completed
Location   Texas Health Presbyterian Dallas
Principal Name    Haskell McGill Kirkpatrick MD
Contact Name   Lauren Braunfeld
Phone   (214) 345-2619

Online Tools


Helpful Info